LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

by OncoDNA

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

by Universitat Rovira i Virgili

Photos Stream